Four-year longitudinal multicenter susceptibility trends of aztreonam–avibactam and ceftazidime–avibactam and dose optimization in critically ill patient populations against carbapenem-resistant Enterobacterales bloodstream infections
Four-year longitudinal multicenter susceptibility trends of aztreonam–avibactam and ceftazidime–avibactam and dose optimization in critically ill patient populations against carbapenem-resistant Enterobacterales bloodstream infections. // Engineering Microbiology. – URL: https://www.sciencedirect.com/science/article/pii/S266737032600055X?dgcid=rss_sd_all
Four-year longitudinal multicenter susceptibility trends of aztreonam–avibactam and ceftazidime–avibactam and dose optimization in critically ill patient populations against carbapenem-resistant Enterobacterales bloodstream infections. Engineering Microbiology. https://www.sciencedirect.com/science/article/pii/S266737032600055X?dgcid=rss_sd_all
“Four-year longitudinal multicenter susceptibility trends of aztreonam–avibactam and ceftazidime–avibactam and dose optimization in critically ill patient populations against carbapenem-resistant Enterobacterales bloodstream infections.” Engineering Microbiology.
@article{article3457,
title = {Four-year longitudinal multicenter susceptibility trends of aztreonam–avibactam and ceftazidime–avibactam and dose optimization in critically ill patient populations against carbapenem-resistant Enterobacterales bloodstream infections},
journal = {Engineering Microbiology},
url = {https://www.sciencedirect.com/science/article/pii/S266737032600055X?dgcid=rss_sd_all}
}